A small study testing the pharmacodynamic effects of several antiplatelet agents suggests that tirofiban (Aggrastat; Medicure), a glycoprotein IIb/IIIa inhibitor, may provide “more potent and ...

Please provide your email address to receive an email when new articles are posted on . The study, which was presented at the virtual PCR e-Course and simultaneously published in Circulation, also ...

This page lists all known medications that could potentially lead to 'Platelet aggregation inhibition' as a side effect. It's important to note that mild side effects are quite common with medications ...

Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and ...

Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container. Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container.

AGGREGATION of platelets in the presence of adenosine diphosphate (ADP) appears to be important in hæmostasis and in the genesis of platelet thrombosis. There is evidence that this reaction is common ...

Background PRAGUE-8: Duration of Clopidogrel Before Elective Angiography vs Before Percutaneous Coronary Intervention Platelet Aggregation: Prasugrel vs Clopidogrel in Aspirin-treated Patients ...

Stockholm, Sweden - A clinical study of clopidogrel loading dose (LD) has found that a 300-mg LD delivered anytime from 3 to 24 hours prior to elective coronary stenting improves platelet inhibition.

Please provide your email address to receive an email when new articles are posted on . A higher dose of a glycoprotein VI inhibitor in patients with CAD who underwent PCI resulted in more pronounced ...

SAN DIEGO---CeleCor Therapeutics, Inc. today announced preliminary positive results in the company’s ongoing phase 1 clinical study with RUC-4, a novel subcutaneous platelet GPIIb/IIIa inhibitor, ...

SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. announced positive data from the company’s completed phase 1 clinical study of RUC-4 which was published in the Journal of the American Heart ...

OBJECTIVE: To investigate the effects of leptin on platelet aggregation and platelet free calcium (Ca 2+) concentrations, and the role of the long form of leptin receptor (ObRb) and the phospholipase ...